4.Basset M, Milani P, Foli A, et al. Earlycardiacresponse is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival [J]. Blood, 2022, 140 (18): 1964-1971. 5.Muchtar E, Dispenzieri A, Wisniowski B, et al. Graded cardiac response criteria for patient...
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history studydoi:10.1038/S41408-021-00529-WAndrew StaronLuke ZhengGheorghe DorosVaishali SanchorawalaNature Publishing Group
Primary amyloidosis has a variable course, but is generally associated with a short life expectancy. To date, no specific therapy has been available. Fifty-three patients with AL amyloidosis seen between 1976 and 1983 were treated with colchicine, and their clinical course and survival were compared...
Gertz MA, Cohen AD, Comenzo RL, et al. Survival benefit of birtamimab in Mayo stage IV AL amyloidosis in the phase 3 VITAL study consistent after adjustment for key baseline variables. Presented at: 2022 ASH Annual Meeting; December 10-13, 2022; New Orleans, ...
Birtamimab demonstrated a significant survival benefit in patients with Mayo Stage IV amyloid light chain amyloidosis at month 9.
Definition of the disease AL amyloidosis results from extra-cellular deposition of fibril-forming monoclonal immunoglobulin (Ig) light chains (LC) (most commonly of lambda isotype) usually secreted by a small plasma cell clone. Most patients have evidence of isolated monoclonal gammopathy or smoldering...
at an increased risk of early mortality. The determination of frailty in amyloidosis is not accompanied by specific frailty scores, but short-term survival can be used as a surrogate to estimate frailty. Age and the number, type and extent of organ involvement and to a lesser extent, pre-exi...
Half of patients with AL amyloidosis present with symptomatic heart failure, a major factor affecting survival. BDex+AA has emerged as the treatment of choice in all-comers with AL amyloidosis because of improved response rates, but there are no direct mortality data confirming benefit in patients...
AL amyloidosis is a life-threatening disease related to bone marrow cancer and multiple myeloma. It is caused when a person's antibody-producing white blood cells (i.e. plasma cells) do not function properly and generate abnormal protein which misfolds t
On multivariate analysis, light chain type remained an independent predictor of survival. Light chain type predicts organ involvement and survival in patients with AL amyloidosis receiving stem cell transplant. Visual Abstract Download: Download high-res image (61KB) Download: Download full-size image...